Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is Chief of Clinical Trials, Professor of Cancer Research and Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Centre Tom Powles is Director of Barts Cancer Centre, St Bartholomews Hospital and Professor or Genitourinary oncology, Queen Mary University of London
…
continue reading
Experts at Queen Mary University of London
…
continue reading
This is a podcast from the Centre for the History of Emotions at Queen Mary, University of London. 'The Sound of Anger' won two gold British Podcast Awards in 2020. Subscribe on Apple Podcasts via iTunes here: https://itunes.apple.com/gb/podcast/living-with-feeling/id1186251350?mt=2
…
continue reading
Magic comes to Mile End with Brent Morris, Arthur Benjamin and Colm Mulcahy.
…
continue reading
Queen Mary, University of London is one of the UK's leading research-focused higher education institutions. With around 16,900 students and 3,800 staff, we are one of the biggest University of London colleges. We teach and research across a wide range of subjects in the humanities, social sciences, law, medicine and dentistry, and science and engineering. Based in a creative and culturally diverse area of east London, we are the only London university able to offer a completely integrated re ...
…
continue reading
Experts on Camera
…
continue reading
Stage left podcast explores performers' approaches to making their work. I teach and write about contemporary theatre and performance at Queen Mary University of London.
…
continue reading
Young journalists from The Print (the student newspaper of Queen Mary University of London), discuss issues affecting students in this podcast.
…
continue reading
Internal launch of the life sciences initiative
…
continue reading
![Artwork](/static/images/128pixel.png)
1
David Willetts MP, Inaugural John Ramsden Memorial Lecture: Liberal Conservatism
Queen Mary, University of London
What can Liberal Conservatism do for you? The Seventy-Sixth Mile End Group event was given by David Willetts MP on the nature of Liberal Conservatism. David Linsay Willetts (born 9 March 1956) is a British Conservative Party politician and the Minister of State for Universities and Science. He is the Member of Parliament (MP) representing the constituency of Havant in Hampshire. This memorial lecture is a tribute to the life and work of John Ramsden, an eminent historian, politician and memb ...
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Professor Joseph Nye, The 2nd Michael Quinlan Lecture: What is Ethical Foreign Policy Leadership?
Queen Mary, University of London
How can we decide what is appropriate in the sphere of global politics? Prof. Joseph Nye, eminent academic, author, and politician with expertise in the field of foreign policy, defense, diplomacy and terrorism talks about his experiences within foreign policy and how he has come to his conclusions using examples like the Iraq war and nuclear weapons. For more information go to www.meg.qmul.ac.uk.
…
continue reading
…
continue reading
What makes a prolific political figure tick? Alastair John Campbell (born 25 May 1957) is a British journalist, broadcaster, political aide and author, best known for his work as Director of Communications and Strategy for Prime Minister Tony Blair between 1997 and 2003. In this interview from 20th June at Mile End Group, Alastair explores his recent autobiography, recounting the key parts of his, and Tony Blair's, career in politics, from the Iraq war to 9/11, and even the Premier's relatio ...
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Today's Neuroscience, Tomorrow's History - Professor Geoffrey Burnstock
Professor Geoffrey Burnstock
Supported by a Wellcome Trust Public Engagement grant (2006-2008) in the History of Medicine to Professor Tilli Tansey (QMUL) and Professor Leslie Iversen (Oxford), the History of Modern Biomedicine Research Group at Queen Mary, University of London presents a series of podcasts on the history of neuroscience featuring eminent people in the field: Professor Burnstock returned to London in 1975, becoming Head of Department of Anatomy and Developmental Biology at University College London and ...
…
continue reading
Supported by a Wellcome Trust Public Engagement grant (2006-2008) in the History of Medicine to Professor Tilli Tansey (QMUL) and Professor Leslie Iversen (Oxford), the History of Modern Biomedicine Research Group at Queen Mary, University of London presents a series of podcasts on the history of neuroscience featuring eminent people in the field: Professor Roger Ordidge studied physics at the University of Nottingham, and went on to obtain his PhD in 1981 under the supervision of Professor ...
…
continue reading
Strategies for Bending Time in Music
…
continue reading
Professor Jack Cuzick discusses IBIS-I breast cancer research
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Study undergraduate medicine in Malta with a top UK medical school
Queen Mary University of London
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Today's Neuroscience, Tomorrow's History - Professor Elizabeth Warrington
Professor Elizabeth Warrington
Supported by a Wellcome Trust Public Engagement grant (2006-2008) in the History of Medicine to Professor Tilli Tansey (QMUL) and Professor Leslie Iversen (Oxford), the History of Modern Biomedicine Research Group at Queen Mary, University of London presents a series of podcasts on the history of neuroscience featuring eminent people in the field: Professor Elizabeth Warrington completed her PhD on visual processing at the Institute of Neurology, London, and was formerly head of the Departme ...
…
continue reading
In this video, we see that mice that are given toys and placed in stimulating surroundings have healthier immune systems.
…
continue reading
📡 EURO—VISION 🛰 the podcast. A series of weekly podcasts that compile conversations with activists, scholars, fisherpeople and artists, hosted by FRAUD, around the politics of extraction, migration and international agreements that are affecting communities and ecologies on a global scale and that perpetuate European colonial legacies. Speakers include: 📢 Prof. Adekeye Adebajo, Director of the Institute for Pan-African Thought and Conversation at the University of Johannesburg, South Africa. ...
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 386: ASCO GU 2025 - APRI Meta-analysis
28:58
28:58
Play later
Play later
Lists
Like
Liked
28:58Tanya Dorff from City of Hope joins us to discuss clinical implications of these data and also comment on TALAPRO-2
…
continue reading
Neeraj Aggarwal joins Tom and Brian for an in-depth look at these important data
…
continue reading
Silke Gillessen joins Brian and Tom and they discuss what to look forward to in prostate, bladder and RCC at ASCO GU 2025.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 383: A Neoantigen Vaccine Generates Anti-tumor Immunity in RCC
33:11
33:11
Play later
Play later
Lists
Like
Liked
33:11David Braun joins the show to discuss his Nature paper on a personalized RCC vaccine
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 382: Uromigos Japan - TROPICs-04の考察
29:48
29:48
Play later
Play later
Lists
Like
Liked
29:48残念ながらNegative StudyとなったTROPICs-04についてUromigosJapanの3人が忖度なしに、その原因や理由について考察をします!!
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 381: Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade
40:05
40:05
Play later
Play later
Lists
Like
Liked
40:05Romain Banchereau joins the show to discuss and debate this Cancer Cell paper on molecular subtypes in urothelial cancer and implications for checkpoint blockade.
…
continue reading
Shankar Siva joins the show to discuss the emerging role of stereotactic body radiotherapy (SBRT) in primary and metastatic RCC tumors.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 379: Uromigos Japan: 2024年のGU Oncologyを振り返る
31:31
31:31
Play later
Play later
Lists
Like
Liked
31:313人による2024年のGU oncoloyのレビューを切れ味鋭く解説しています。乞うご期待!
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 378: 2025 Preview of Important GU Data
41:42
41:42
Play later
Play later
Lists
Like
Liked
41:42Tanya Dorff from City of Hope joins Brian and Tom to review what to expect throughout 2025 and beyond in terms of clinically impactful data in prostate, renal and bladder cancer
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 377: Prostate Cancer 2024 Highlights
35:12
35:12
Play later
Play later
Lists
Like
Liked
35:12Silke Gilleson gives Tom and Brian 3 'gifts': Thomas Zilli (Radiation Oncology), Jochen Walz (Urology) and Ken Hermann (Nuclear Medicine) who discuss the 2024 prostate highlights from each of their unique perspectives.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 376: Bladder Cancer 2024 Highlights
25:37
25:37
Play later
Play later
Lists
Like
Liked
25:37Matt Galsky joins Brian and Tom to discuss the most impactful data in bladder cancer form the past year.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 375: Renal Cancer 2024 Highlights
43:11
43:11
Play later
Play later
Lists
Like
Liked
43:11David McDermott (and his dog, Finn) join the show to review the top data from 2024 in RCC
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 374: Mechanisms of HIF Resistance
34:37
34:37
Play later
Play later
Lists
Like
Liked
34:37Jim Brugarolas joins to discuss his talk from IKCS 2024 and the board topic of resistance to HIF inhibitors.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 373: KEYNOTE-564 Asian OSとANNARの解説
34:05
34:05
Play later
Play later
Lists
Like
Liked
34:05JSCO2024で発表されたKEYNOTE-564東アジア人OSデータとANNAR biomarker studyの解説とディスカッションです
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 372: FDA Accelerated Approval Process
31:30
31:30
Play later
Play later
Lists
Like
Liked
31:30Dan Suzman from FDA joins us to discuss the Accelerated Approval process, requirements, successes and challenges.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 371: TROPICS-04 Results from ESMO Asia
33:43
33:43
Play later
Play later
Lists
Like
Liked
33:43Jonathan Rosenberg joins Brian and Tom to discuss this important phase 3 trial and efficacy and toxicity signals.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 370: Artificial Intelligence in Medical Oncology
44:46
44:46
Play later
Play later
Lists
Like
Liked
44:46Jacob Kather joins Brian and Tom to discuss emerging AI applications in Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 369: Paper of the Month with Bishoy Faltas
45:51
45:51
Play later
Play later
Lists
Like
Liked
45:51Bishoy joins us to discuss his work on extrachromosomal DNA in bladder cancer from his latest Nature publication
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 368: Radiomics in RCC: Live from IKCS
37:00
37:00
Play later
Play later
Lists
Like
Liked
37:00Andrew Smith from St. Jude's joins us to discuss the emerging field of radiomics and shares his hopes and skepticism
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 367: Abiraterone vs AR inhibitors (Fanta vs Coke) in Prostate Cancer
56:48
56:48
Play later
Play later
Lists
Like
Liked
56:48Chuck Ryan from MSKCC joins to talk about various aspects of AR inhibition in prostate cancer and relative benefits and risks.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 366: ARPIs in Prostate Cancer - Are They Different?
31:51
31:51
Play later
Play later
Lists
Like
Liked
31:51Chris Sweeney and Rob Jones join Brian and Tom to discuss the relative merits of different ARPIs in prostate cancer.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 365: A Review of the Advanced Prostate Cancer Consensus Conference (APCCC)
47:59
47:59
Play later
Play later
Lists
Like
Liked
47:59Episode 365: Silke Gillessen and Betrand Tombal join the show to discuss the APCCC meeting and recent publication.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 364: 腎がんの最新の話題〜IO rechallengeと乳頭型腎がんの治療戦略〜
15:41
15:41
Play later
Play later
Lists
Like
Liked
15:41腎がんの最新の話題〜IO rechallengeと乳頭型腎がんの治療戦略〜
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 363: 前立腺がんの最新の話題〜T cell directed therapyとradioligands〜
14:23
14:23
Play later
Play later
Lists
Like
Liked
14:23前立腺がんの最新の話題〜T cell directed therapyとradioligands〜
…
continue reading
膀胱がんの最新の話題〜周術期薬物療法とADC〜
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 361: The Role of Monotherapy AR Inhibition in Prostate Cancer
25:43
25:43
Play later
Play later
Lists
Like
Liked
25:43Betrand Tombal joins Brian and Tom to discuss the historic and current data for AR inhibition with monotherapy with AR blockers.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 360: The SUNRISE Program in Bladder Cancer
46:19
46:19
Play later
Play later
Lists
Like
Liked
46:19Christopher Cutie from J&J joins the show to discuss the SUNRISE bladder program with the gemcitabine-eluting pretzel across several NMIBC and MIBC states.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 359: #UromigosLive24 - IO after IO in RCC
40:41
40:41
Play later
Play later
Lists
Like
Liked
40:41The RCC panel at Uromigos Live 2024 discusses and debates this topic.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 358: Noticias del Dia 1 de Uromigos Live 2024 en Nashville
21:59
21:59
Play later
Play later
Lists
Like
Liked
21:59Eneste podcast cubrimos los temas de cáncer urotelial discutidos por los Uromigos. El impacto del estudio NIAGARA en utiliar quimio más inmunoterapia enneadyuvancia de Ca urotelial músculo invasor, el uso de pembrolizumab adyuvante después de los datos del estudio AMBASSADOR y la búsqueda de biomarcadores.…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 357: #UromigosLive24 - Peri-operative Therapy in Bladder Cancer
1:03:10
1:03:10
Play later
Play later
Lists
Like
Liked
1:03:10Tom leads a panel of Shilpa Gupta, Andrea Apolo, Kala Sridhar and Petros Grivas to discuss and debate this timely topic.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 356: #UromigosLive24 - Front-line Therapy in Papillary and Non-clear Cell RCC
26:22
26:22
Play later
Play later
Lists
Like
Liked
26:22Brian moderates the panel that discusses and debates TKI, vs Ipi/Nivo vs IO/TKI
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 355: #UromigosLive24 - Radioligands in prostate cancer
54:23
54:23
Play later
Play later
Lists
Like
Liked
54:23The Uromigos Live 2024 panel discusses recent radioligand data including PEACE-3
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 354: #UromigosLive24 - T cell directed therapy in prostate cancer
44:00
44:00
Play later
Play later
Lists
Like
Liked
44:00Brian hosts a panel at Uromigos Live 2024 in Nashville with Michael Morris, Tanya Dorff and Karen Autio
…
continue reading
Tom moderates a live panel of Kala Sridhar, Shilpa Gupta, Andrea Apolo and Petros Grivas on the emerging ADC data in bladder cancer
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 352: ESMO 2024 - RCC and Bladder review
26:25
26:25
Play later
Play later
Lists
Like
Liked
26:25Tom and Brian finish discussing ESMO 2024 highlights. Even without a guest Tom still interrupts a lot.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 351: ESMO 2024 review part 1: prostate cancer
18:48
18:48
Play later
Play later
Lists
Like
Liked
18:48Silke joins us to discuss ESMO 2024 highlights, then the birds start singing....
…
continue reading
Fresh of the Presidential session address, Tom discusses his data with Petros commenting.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 349: ESMO 2024 - Uromigos Japan!!
30:56
30:56
Play later
Play later
Lists
Like
Liked
30:56Uromigos Japan with Yuji, Hiroshi and Nobu is formed and discuss Hiroshi's ESMO data.
…
continue reading
Arun Azad describes this randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel vs. docetaxel in mHSPC
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 347: ESMO 2024 - DV + Pembro in Urothelial Cancer
17:59
17:59
Play later
Play later
Lists
Like
Liked
17:59Matt Galsky describes his ESMO 2024 abstract of disitimab vedotiin + pembrlizumab in bladder cancer
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 346: ESMO 2024 - PEACE-3: Enza/Radium-223 vs Enza in mCRPC
25:47
25:47
Play later
Play later
Lists
Like
Liked
25:47Silke Gillessen joins us to discuss her Presidential session from ESMO 2024
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 345: ESMO 2024 - SUNNIFORECAST: Ipi/Nivo vs SOC in Non-clear Cell RCC
31:10
31:10
Play later
Play later
Lists
Like
Liked
31:10Lothar Bergmann describes this investigator-initiated trial of Ipi/Nivo vs SOC in Non-clear Cell RCC
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 344: ESMO 2024 - NKT2152, a HIF inhibitor in RCC
22:32
22:32
Play later
Play later
Lists
Like
Liked
22:32Brad McGregor joins Brian and Tom to discuss a new HIF inhibitor, NKT2152, and preliminary data in RCC
…
continue reading
Katy Beckermann discusses the TiNivo-2 study presented at ESMO 2024.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 342: ESMO 2024 Preview with Silke Gillessen
32:24
32:24
Play later
Play later
Lists
Like
Liked
32:24Silke joins Brian and Tom to discuss upcoming data in prostate, bladder and kidney cancer in Barcelona at ESMO 2024
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 341: Hormone Resistance in Prostate Cancer
33:05
33:05
Play later
Play later
Lists
Like
Liked
33:05Nima Sharifi joins Brian and Tom to discuss mechanisms of resistance to hormone therapy in prostate cancer
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 340: Cancer Immunity Cycle Update
41:50
41:50
Play later
Play later
Lists
Like
Liked
41:50Ira Mellman delves into the update of this classic paper and the components of an effective anti-tumor immune response.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 339: Tres Uramigas analizan lineamientos de ESMO para GU
18:37
18:37
Play later
Play later
Lists
Like
Liked
18:37María, Christina y Elena analizan los cambios recientes en las directrices de la ESMO en el cáncer de riñón, vejiga y próstata.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 338: RCC: Debulking Nephrectomy, Adjuvant Therapy Future and More
25:39
25:39
Play later
Play later
Lists
Like
Liked
25:39Naomi Haas joins Tom and Brian in New York City at the World GU Conference to discuss several RCC topics
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 337: Updated NCCN Guidelines in RCC
42:38
42:38
Play later
Play later
Lists
Like
Liked
42:38Eric Jonasch, Co-Chair of the NCCN RCC Guidelines, gives insight into the process of guideline modification and discusses updates in adjuvant, front-line and refractory RCC
…
continue reading